Edwards Life (EW) Offering Possible 21.08% Return Over the Next 22 Calendar Days

Edwards Life's most recent trend suggests a bullish bias. One trading opportunity on Edwards Life is a Bull Put Spread using a strike $76.67 short put and a strike $71.50 long put offers a potential 21.08% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $76.67 by expiration. The full premium credit of $0.90 would be kept by the premium seller. The risk of $4.27 would be incurred if the stock dropped below the $71.50 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Edwards Life is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Edwards Life is bullish.

The RSI indicator is at 75.93 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Edwards Life

The Top 5 Trades of the Eaton Vance Worldwide Health Sciences Fund
Mon, 27 Jul 2020 19:18:39 +0000
Health care-focused fund releases 2nd-quarter portfolio Continue reading…

Edwards Inches Closer To Breakout On $100 Million Heart-Valve Beat
Fri, 24 Jul 2020 20:24:14 +0000
Edwards Lifesciences handily topped Wall Street's second-quarter expectations amid a resurgence in heart-valve replacements. EW stock inched slightly closer to a buy point Friday.

P/E Ratio Insights for Edwards Lifesciences
Fri, 24 Jul 2020 13:48:00 +0000
In the current session, Edwards Lifesciences Inc. (NYSE: EW) is trading at $77.38, after a 0.05% rise. Over the past month, the stock increased by 20.14%, and in the past year, by 11.87%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 68.75%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.View more earnings on EWMost often, an industry will prevail in a particular phase of a business cycle, than other industries.Edwards Lifesciences Inc. has a lower P/E than the aggregate P/E of 150.61 of the Medical Devices industry. Ideally, one might believe that they might perform worse than its peers, but it's also probable that the stock is undervalued.Price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * Edwards Lifesciences: Q2 Earnings Insights * Earnings Scheduled For July 23, 2020 * Stocks That Hit 52-Week Lows On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Ups EPS View
Fri, 24 Jul 2020 13:22:01 +0000
Despite coronavirus-hit sales, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q2. Regulatory approvals look encouraging.

Edwards Lifesciences Blows Past Q2 Earnings Estimates
Fri, 24 Jul 2020 10:03:00 +0000
Investors might not be overly excited about Edwards Lifesciences' (NYSE: EW) stock performance so far in 2020. Edwards Lifesciences announced its second-quarter results after the market closed on Thursday, and the stock jumped 5% in after-hours trading.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.